P. D. O. Davies (Liverpool, United Kingdom), T. Mihaescu (Iasi, Romania)
Linezolid in multidrug-resistant tuberculosis treatment
E. H. Abbate, A. Brea, M. Cufré, M. Vescovo, A. García, M. Ambroggi, N. Símboli, E. Rizzuti, E. Bonazzi (Buenos Aires, Argentina)
|  |
The possibility of strengthening of activity of antituberculous drugs: preliminary results
E. V. Kulchavenya, G. M. Lisichenko (Novosibirsk, Russia)
|  |
Efficiency of new antimycobacterial preparation isofon in children and teenagers with tuberculosis
Z. I. Kryvasheyeva, P. S. Krivonos, A. S. Pozdnyakova, N. A. Emeljanova, A. M. Scrahina, N. S. Morozkina, Z. V. Lavor (Minsk, Belarus)
| |
Experience of isofon use for therapy and chemoprophylaxis of tuberculosis
P. S. Kryvanos, G. S. Avdeev, O. M. Kaletchits, L. K. Surcova, N. S. Shpakovskay, I. A. Verestchagina, L. I. Bortkevich, S. N. Kosmachova, V. N. Shamshur, S. I. Komsa, A. F. Grinevich (Minsk, Belarus)
| |
The efficacy of interferon-alpha in treating multi-drug resistant tuberculosis
S. Tavana, D. S. Mansouri, M. S. Mirsaeidi, M. Yazdanpanah, H. Sohrabpour (Hamedan, Tehran, Iran)
| |
Outlook of the treatment with unazyn of drug-resistant tuberculosis forms and non-specific diseases of the breathing organs
E. S. Belova, G. B. Rakishev, K. S. Serikbaeva (Almaty, Kazakhstan)
| |
Effectiveness of integrated DOTS and DOTS-Plus in Latvia
V. Leimane, J. Leimans, V. Riekstina, E. Zarovska (Riga, Latvia)
| |
Changes in the quantity of 1b-interleukin (IL-1b), tumor necrosis factor-a (TNF-a) and interferon-g (IF-g) in evaluation of the effectiveness of treatment of tuberculosis by DOTS
M. D. Safaryan, A. V. Gasparyan (Yerevan, Armenia)
| |